



US009517219B2

(12) **United States Patent**
Warner et al.

(10) **Patent No.:** **US 9,517,219 B2**
(45) **Date of Patent:** **Dec. 13, 2016**

(54) **TOPICAL DAPSONE AND DAPSONE/ADAPALENE COMPOSITIONS AND METHODS FOR USE THEREOF**

(71) Applicant: **Allergan, Inc.**, Irvine, CA (US)

(72) Inventors: **Kevin S. Warner**, Anaheim, CA (US);
Ajay P. Parashar, Fairfax, VA (US);
Vijaya Swaminathan, San Francisco, CA (US);
Varsha Bhatt, San Francisco, CA (US)

(73) Assignee: **Allergan, Inc.**, Irvine, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/885,805**

(22) Filed: **Oct. 16, 2015**

(65) **Prior Publication Data**

US 2016/0030580 A1 Feb. 4, 2016

Related U.S. Application Data

(62) Division of application No. 14/082,955, filed on Nov. 18, 2013, now Pat. No. 9,161,926.

(60) Provisional application No. 61/728,403, filed on Nov. 20, 2012, provisional application No. 61/770,768, filed on Feb. 28, 2013.

(51) **Int. Cl.**

A61K 31/136 (2006.01)
A61K 31/192 (2006.01)
A61K 9/00 (2006.01)
A61K 31/145 (2006.01)
A61K 47/32 (2006.01)
A61K 47/10 (2006.01)
A61K 47/14 (2006.01)
A61K 47/18 (2006.01)
A61K 47/34 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 31/192** (2013.01); **A61K 9/0014** (2013.01); **A61K 31/136** (2013.01); **A61K 31/145** (2013.01); **A61K 47/10** (2013.01); **A61K 47/14** (2013.01); **A61K 47/183** (2013.01); **A61K 47/32** (2013.01); **A61K 47/34** (2013.01)

(58) **Field of Classification Search**

None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,532,219 A * 7/1996 McGeer A61K 31/145 514/42
5,863,560 A 1/1999 Osborne
5,989,571 A * 11/1999 Santa A61K 9/12 424/401
6,060,085 A 5/2000 Osborne
6,620,435 B1 9/2003 Osborne
7,531,694 B2 5/2009 Villa et al.
8,586,010 B2 * 11/2013 Garrett A61K 8/46 424/59
9,161,926 B2 * 10/2015 Warner A61K 9/0014
2006/0204526 A1 9/2006 Lathrop et al.
2010/0029781 A1 2/2010 Morris
2010/0130613 A1 5/2010 Dreno
2012/0064144 A1 * 3/2012 Benhamou A61K 9/7023 424/443

FOREIGN PATENT DOCUMENTS

WO WO 2009/061298 A1 * 5/2009
WO 2009-108147 9/2009
WO WO 2009/108147 A1 * 9/2009
WO WO 2010/105052 A1 * 9/2010
WO WO2010105052 A1 9/2010
WO WO2011-014627 2/2011
WO WO 2011/014627 A1 * 2/2011

OTHER PUBLICATIONS

Draelos, Zoe D. et al., Two Randomized Studies Demonstrate the Efficacy and Safety of Dapsone Gel, 5% for the Treatment of Acne Vulgaris, Journal of American Academy of Dermatology, Mar. 2007, 26 Pages, 56, US.
Lubrizonl (Online). "Viscosity of CARBOPOL Polymers in Aqueous Systems". (Retrieved Mar. 18, 2014). Retrieved from the Internet<URL:http://www.lubrizonl.com/Life-Science/Documents/Pharmaceutical/Technical-Data-Sheets/TDS-730-Viscosity-Carbopol-in-Aqueous-Systems.pdf>.
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, International Application No. PCT/US2013/070613, International Filing Date, Nov. 18, 2013, Date of Mailing Feb. 12, 2014.

* cited by examiner

Primary Examiner — Leslie A. Royds Draper
(74) Attorney, Agent, or Firm — Laura L. Wine


(57) **ABSTRACT**

Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder.


8 Claims, 3 Drawing Sheets

Figure 1. Appearance of formulations following 4 weeks of storage

A1 at initial timepoint



A2 at initial timepoint



A1 after 4 weeks storage at 25°C



A2 after 4 weeks storage at 25°C



A1 after 4 weeks storage at 40°C



A2 after 4 weeks storage at 40°C



Figure 2. Polarized light images of dapsone in suspension formulations








Figure 3. Appearance of formulations with antioxidants or chelating agents over 4 weeks



1

**TOPICAL DAPSONE AND
DAPSONE/ADAPALENE COMPOSITIONS
AND METHODS FOR USE THEREOF**

CROSS REFERENCE TO RELATED
APPLICATIONS

This application is a divisional of copending U.S. patent application Ser. No. 14/082,955, filed on Nov. 18, 2013, which claims the benefit of U.S. Provisional Application Ser. No. 61/728,403 filed on Nov. 20, 2012 and U.S. Provisional Application Ser. No. 61/770,768 filed on Feb. 28, 2013, all of which are incorporated by reference herein in their entirety.

FIELD

The present embodiments relate generally to compositions useful for treating a variety of dermatological conditions. In particular, some embodiments relate to dapsone and dapsone/adapalene compositions and methods for use thereof.

BACKGROUND

Acne is a group of common skin conditions characterized by the so-called “acneiform” or acne-like skin eruptions, which can be contaminated with bacteria, such as *Propionibacterium acnes*, and can also be marked by inflammation. Acne tends to occur in the areas of skin where the sebaceous glands are most active, such as the face. Acne is associated with psychological trauma, and, if left untreated, can lead to scar formation and disfigurement.

Classification and the diagnosis of various acne conditions can be complex, and even contradictory. Given this complexity and unpredictability, medication and other therapies, are often developed on a trial-and-error basis in order to determine the most effective course of treatment for a particular patient. The outcome of any particular acne treatment regimen greatly varies from patient to patient, as well as throughout treatment of a particular patient. In addition to the complexity and variability of acne conditions, treatment efficacy can be greatly affected by a patient’s compliance with the treatment regimen. Patient compliance during acne treatment may be influenced by side effects, which, for topical medications, commonly include redness, itching, and skin peeling. The complexity of the drug regimen can also negatively affect patient compliance, particularly where two or more different topical medications are prescribed simultaneously. Another factor that negatively affects patient compliance is the cost of a drug regimen, which is considerably higher when multiple medications are prescribed. In some countries, acne is considered a cosmetic problem, and acne treatments are not covered by insurance plans, thus further increasing patient’s treatment costs. Certain compositions for treatment of acne are available. Many of the available compositions include one active agent known to have anti-acne activity. Stability of compositions with multiple anti-acne agents can be problematic. Also, these compositions can be difficult to manufacture.

The problems described above are not confined to the treatment of acne, but are also applicable to a variety of other skin conditions, including, but not limited to, conditions or classes of conditions with complex or unknown etiology and

2

at least in some cases. Examples of such conditions or classes of conditions include psoriasis, rosacea and ichthyosis.

Accordingly, there is a continuing need for compositions and methods used in a treatment of a variety of skin conditions, such as acne, in which topical application is potentially effective. The compositions and methods provided herein address these and other needs in the art.

SUMMARY

Dapsone, (4,4'-diaminodiphenyl sulfone) is a medicament possessing several beneficial medicinal activities. Dapsone is typically administered as one of the medicinal agents used in the treatment of leprosy. Dapsone and its derivatives are also effective for treatment of bacterial infections, protozoal infections such as malaria, *pneumocystis carinii*, and plasmonic infections such as toxoplasmosis.

Dapsone is also useful as an anti-inflammatory agent. It has been used to treat skin diseases characterized by the abnormal infiltration of neutrophils, such as Dermatitis herpetiformis, linear IgA dermatosis, pustular psoriasis, pyoderma gangrenosum, acne vulgaris, and Sweet’s Syndrome.

Use of topical compositions of dapsone can be problematic. Topical compositions may act as drying agents for the skin. They remove essential oils and natural skin softeners from the skin thus causing it to be dry, itch and crack. Inclusion of exogenous skin emollients, oils and the like, however, causes phase separation and precipitation of dapsone. Use of typical emulsifiers does not solve the dapsone precipitation owing to the lowered dapsone solubility and conflicting physical characteristics of the phases of the resulting composition. In particular, topical compositions including dapsone and methods are needed that would, for example, exhibit improved effectiveness, reduced side effects, or both, when used in a particular patient with a skin condition. Such improved topical compositions including dapsone and methods of their uses are also needed to improve treatment of patients with acne or suspected acne. The present dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. Some useful compositions include dapsone and/or adapalene in a polymeric viscosity builder. Some compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Diethylene glycol monoethyl ether is a solubilizer for dapsone, thereby allowing compositions to be prepared with increased solubilized concentrations of dapsone. As a result, the compositions described herein are effective in treating dermatological conditions in a subject in need thereof.

Moreover, it has been found that use of a polymeric viscosity builder minimizes the intensity of yellowing of the composition caused by the increased solubility of dapsone in diethylene glycol monoethyl ether. In addition, the polymeric viscosity builder influences dapsone crystallization. This, in turn, results in compositions with improved aesthetics (i.e., reduction in particle size which minimizes “gritty” feeling upon application).

In one embodiment, there are provided compositions including dapsone, a first solubilizing agent which is diethylene glycol monoethyl ether, optionally at least one second solubilizing agent, a polymeric viscosity builder, and water,

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.